[유상증자 모니터] 툴젠, 700억 조달…특허전 실탄 마련

Toolgen's 70 billion won fundraising represents a strategic pivot from pure R&D to commercializing CRISPR patent victories, particularly as its dispute with Broad Institute over foundational gene-editing technology resumes. The company must manage aggressive patent litigation while controlling cash burn before patent wins translate into actual licensing revenues by 2026-2027. This capital raise essentially buys time to establish dominant IP position before patent monetization materializes into cash flow.